Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157513 | 1.00 | CTSK (0.43) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL15156428 | 1.00 | CTSK (0.43) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL14497053 | 0.88 | CYP1A2 (0.41) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL29389345 | 0.87 | HDAC4 (0.45) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL17080907 | 0.87 | CYP1A2 (0.40) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL19326572 | 0.87 | CYP1A2 (0.40) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL21437807 | 0.87 | CTSK (0.44) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL15451952 | 0.87 | CTSK (0.44) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL31240095 | 0.87 | CYP1A2 (0.40) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL15083489 | 0.84 | CTSK (0.46) | CTSKCTSSPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-9309284-B2 | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses | Kansas State University Reasearch Foundation (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150133368-A1 | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | WICHITA STATE UNIVERSITY | 2015-05-14 | — | — | US | disclosed |
| EP-2844249-A1 | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | Kansas State University Research Foundation (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013166319-A1 | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-11-07 | — | — | WO | disclosed |
| US-7939626-B2 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-10 | — | — | US | disclosed |
| US-7838665-B2 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-23 | — | — | US | disclosed |
| US-7667012-B2 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product; N-azidogalactosamine | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133368-A1 | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | CTSV, CTSL, GTF3C3 | CTSK 50/4885CTSS 9/4885PPARA 1733/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | CTSK 2840/4885CTSS 3711/4885PPARA 179/4885 |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | PTMS, QPCT, DNPEP | CTSK 1494/4885CTSS 1890/4885PPARA 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.